Natera - Strong Numbers and Japan Approvals Drive Momentum!
Reading Time: 3 minutes
Asia Expansion: Japan's PMDA approves the genetic test Signatera as a companion diagnostic for bladder and colorectal cancer, opening a highly profitable key market. Strong Balance Sheet: A revenue increase of 37.7% in the second quarter and a record volume of over 1.04 million processed tests support the operational momentum. Stock Driver Volume Breakout: Institutional investors accumulate shares under high trading volume following positive US guideline upgrades and advancements in cancer early detection. The US diagnostics company...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
